U.S. markets closed
  • S&P 500

    4,076.57
    -3.54 (-0.09%)
     
  • Dow 30

    34,395.01
    -194.76 (-0.56%)
     
  • Nasdaq

    11,482.45
    +14.45 (+0.13%)
     
  • Russell 2000

    1,881.67
    -4.90 (-0.26%)
     
  • Crude Oil

    81.27
    +0.72 (+0.89%)
     
  • Gold

    1,817.30
    +57.40 (+3.26%)
     
  • Silver

    22.98
    +1.20 (+5.50%)
     
  • EUR/USD

    1.0527
    +0.0119 (+1.15%)
     
  • 10-Yr Bond

    3.5290
    -0.1740 (-4.70%)
     
  • GBP/USD

    1.2245
    +0.0183 (+1.52%)
     
  • USD/JPY

    135.2870
    -2.7930 (-2.02%)
     
  • BTC-USD

    16,895.54
    -163.01 (-0.96%)
     
  • CMC Crypto 200

    400.54
    -5.61 (-1.38%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

What Type Of Shareholders Own The Most Number of SomaLogic, Inc. (NASDAQ:SLGC) Shares?

The big shareholder groups in SomaLogic, Inc. (NASDAQ:SLGC) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

SomaLogic has a market capitalization of US$849m, so we would expect some institutional investors to have noticed the stock. In the chart below, we can see that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about SomaLogic.

View our latest analysis for SomaLogic

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About SomaLogic?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

We can see that SomaLogic does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of SomaLogic, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Hedge funds don't have many shares in SomaLogic. Casdin Capital, LLC is currently the company's largest shareholder with 6.8% of shares outstanding. The second and third largest shareholders are ARK Investment Management LLC and Novartis AG, with an equal amount of shares to their name at 5.7%.

Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 15 shareholders, meaning that no single shareholder has a majority interest in the ownership.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of SomaLogic

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Shareholders would probably be interested to learn that insiders own shares in SomaLogic, Inc.. In their own names, insiders own US$49m worth of stock in the US$849m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

General Public Ownership

The general public, who are usually individual investors, hold a 26% stake in SomaLogic. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 6.8% stake in SomaLogic. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

It seems that Private Companies own 3.7%, of the SomaLogic stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Public Company Ownership

We can see that public companies hold 5.7% of the SomaLogic shares on issue. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand SomaLogic better, we need to consider many other factors. Take risks for example - SomaLogic has 2 warning signs we think you should be aware of.

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.